Back to News
Market Impact: 0.3
DataMEDS AI Buys Helomics Cancer Lab And CRO Assets As Shares Jump 170% In Pre-Market
Source: Nasdaq
M&A & RestructuringArtificial IntelligenceHealthcare & BiotechTechnology & Innovation
DataMEDS AI (MEDS) acquired Helomics AI's cancer diagnostics laboratory and precision-oncology contract research businesses from Axe Compute (AGPU). The transaction expands DataMEDS' presence in AI-driven precision medicine and oncology diagnostics, although no transaction value or financial terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AGPU0.15
MEDS0.60
More News
- Why Wendy’s is losing the burger wars—and is now a takeover target for Nelson Peltz
- Companies promised AI gains— here's how the payoff showed up in earnings
- AWS grows 39% and Amazon will spend even more on AI in 2027
- Stocks started the week with promise but ended in despair. Our take on the big reversal
- Fears over $828 billion AI capex spending spree help erase $1 trillion in market value
- Intel stock plunges 29%. Analysts urge caution on buying the dip
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- How to Automate Equity Research Workflows: A Control-First Guide